May 09, 2024 8:00 am EDT New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
May 04, 2024 8:00 am EDT MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
May 02, 2024 7:00 am EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
Mar 11, 2024 7:00 am EDT MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Mar 07, 2024 7:13 am EST Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
Mar 07, 2024 6:00 am EST MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder